AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04170153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.
Study NCT04170153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally throughout the study.
Study NCT03657628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Strength training and moderate-intensity, aerobic exercise
Study NCT04699591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Domperidone
Description: Domperidone taken 4 times a day, dose based on body weight
Study NCT04340505 — intervention group
Intervention type: DRUG
Intervention: Fluocinolone Acetonide
Description: Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum challenge
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT03173560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib capsules.
Study NCT03173560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus tablets.
Study NCT02444338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: Implantation of the MitraClip System for patients with chronic heart failure.
Study NCT02444338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Study NCT02444338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Study NCT03012399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosedation
Description: Undergo hypnosedation
Study NCT03012399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03012399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03012399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Support
Description: Speak with min-body specialist
Study NCT06591260 — intervention group
Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study NCT06597825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)
Description: After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
Study NCT02484391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV
Study NCT02484391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02484391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo stem cell transplant
Study NCT02484391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT06585800 — intervention group
Intervention type: OTHER
Intervention: sample collection
Description: blood and/or tissue collection
Study NCT02702492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT02702492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER
Study NCT02702492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT04071990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FB-CBGT
Description: CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
Study NCT04071990 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBGT
Description: CBGT for OCD patients, without involvement of family members
Study NCT03735875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study NCT03735875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06589492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of MMP-9 and SIRT-1 levels in blood serum
Description: Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
Study NCT04593927 — intervention group
Intervention type: DRUG
Intervention: Mayzent
Description: There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT03606668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive Virtual Reality (VR) system
Description: VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
Study NCT03657654 — intervention group
Intervention type: OTHER
Intervention: No intervention: observational only
Description: No intervention: observational only
Study NCT03630354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete supervised exercise
Study NCT03630354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete unsupervised exercise
Study NCT03630354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive instructional DVD
Study NCT03630354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06706193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty using CPE
Study NCT06706193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using HXLPE
Study NCT02768311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neolix rotary system (continuous rotation system)
Description: Procedure: neolix rotary system
Study NCT06706466 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: Non-interventional
Study NCT02768311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: waveone rotary system (reciprocating system)
Description: Procedure: waveone rotary system
Study NCT02768311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand files k-files
Description: Procedure: hand files k-files
Study NCT01128374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Scaling and root planing
Description: Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
Study NCT00261690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Using virtual reality distraction during a procedure
Study NCT01024517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 solution
Description: single oral dose, GLPG0259, 50 mg oral solution
Study NCT01024517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: single oral dose, GLPG0259, 50 mg solid formulation
Study NCT02438163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session.
Study NCT00079417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00079417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Study NCT01175954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
Study NCT01175954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
Study NCT02355080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site bundled rapid HIV/HCV testing
Description: Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
Study NCT02355080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Participants will receive the SOC for HIV and HCV testing at the study sites.
Study NCT04539782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Description: Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
Study NCT04318067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin 3 mg is given ones a day - at bedtimes for 6 month
Study NCT01478139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT-plug
Description: Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
Study NCT01478139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT
Description: Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
Study NCT00297232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Study NCT00783900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, biatrial pacing
Description: Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
Study NCT00079417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrared Laser Therapy
Study NCT00079417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-125
Description: Undergo radioactive therapy
Study NCT00079417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radioactive therapy
Study NCT00079417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ruthenium Ru-106
Description: Undergo radioactive therapy
Study NCT00079417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03991221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dental Exam
Description: Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
Study NCT03991221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Orthodontics consult
Description: Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
Study NCT03991221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Call back at 6 month
Description: Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
Study NCT00485979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: intravenous administration
Study NCT00485979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: intravenous administration
Study NCT00485979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: intravenous administration
Study NCT01580878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrimin Ultra®
Description: Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
Study NCT01580878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butenafine Vehicle
Description: Butenafine Vehicle applied twice daily for 7 consecutive days.
Study NCT00485979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: intravenous administration
Study NCT02257567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study NCT02257567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study NCT02064946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 50,000IU/week of vitamin D3
Study NCT02064946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03481088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional appliance therapy
Description: All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)
Study NCT04602663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Variceal Band ligation
Description: Band ligation of OV
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 25G needle, stylet reinserted
Description: Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 25G needle, stylet not reinserted
Description: Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 22G needle, stylet reinserted
Description: Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 22G needle, stylet not reinserted
Description: Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinocan 25G needle, stylet reinserted
Description: Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
Study NCT03960749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinocan 25G needle, stylet not reinserted
Description: Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
Study NCT00546806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programs of Care
Description: Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
Study NCT00546806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programs of Care
Description: Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
Study NCT02209714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIF 1149 BS
Study NCT02209714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03626454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine Bolus
Description: 'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
Study NCT03626454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
Study NCT03626454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: 10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
Study NCT03626454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution
Description: 50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
Study NCT03692208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal Survey and Optional Care Management
Description: The intervention is already described in the intervention arm description.
Study NCT03692208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Diabetes Goal Survey and Optional Care Management
Description: The intervention is already described in the intervention arm description.
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT01747447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study NCT00278343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: 30mg given PO, daily
Study NCT00278343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies